Evidence map›Paper›PMID 31623618›Full record

ArticleCell communication and signaling : CCS2019

Induction of LEF1 by MYC activates the WNT pathway and maintains cell proliferation.

Yi-Heng Hao, M Carmen Lafita-Navarro, Lauren Zacharias, Nofit Borenstein-Auerbach, Min Kim, Spencer Barnes, Jiwoong Kim, Jerry Shay, Ralph J DeBerardinis, Maralice Conacci-Sorrell

Open access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 91 citations in OpenAlex.

  1. The Impact of Targeting TRAF2 and NCK-Interacting Protein Kinase on Antitumor Effect and Tumor Immune Environment in c-MYC-High SCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Knockouts ofiScience · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yi-Heng HaoDepartment of Cell Biology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
M Carmen Lafita-NavarroDepartment of Cell Biology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Lauren ZachariasHoward Hughes Medical Institute and Children's Research Institute, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Nofit Borenstein-AuerbachDepartment of Cell Biology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Min KimLyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Spencer BarnesLyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Jiwoong KimLyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Jerry ShayDepartment of Cell Biology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Ralph J DeBerardinisHoward Hughes Medical Institute and Children's Research Institute, UT Southwestern Medical Center, Dallas, TX, 75390, USA.
Maralice Conacci-SorrellDepartment of Cell Biology, UT Southwestern Medical Center, Dallas, TX, 75390, USA. Maralice.ConacciSorrell@UTSouthwestern.edu.ORCID 0000-0002-4371-5087
Southwestern Medical CenterHoward Hughes Medical Institute · USSouthwestern Medical Center · US

Funding

Metabolic Regulators of Tumor Growth and ProgressionR35CA220449 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI RALPH J DEBERARDINIS · 2017 to 2026
$9.4M
Howard Hughes Medical InstituteNCI NIH HHS R35 CA220449
6 · The paper itself

Abstract

backgroundWhile regulated WNT activity is required for normal development and stem cell maintenance, mutations that lead to constitutive activation of the WNT pathway cause cellular transformation and drive colorectal cancer. Activation of the WNT pathway ultimately leads to the nuclear translocation of β-catenin which, in complex with TCF/LEF factors, promotes the transcription of genes necessary for growth. The proto-oncogene MYC is one of the most critical genes activated downstream the WNT pathway in colon cancer. Here, we investigate the converse regulation of the WNT pathway by MYC.

methodsWe performed RNA-seq analyses to identify genes regulated in cells expressing MYC. We validated the regulation of genes in the WNT pathway including LEF1 by MYC using RT-qPCR, Western blotting, and ChIP-seq. We investigated the importance of LEF1 for the viability of MYC-expressing cells in in fibroblasts, epithelial cells, and colon cells. Bioinformatic analyses were utilized to define the expression of MYC-regulated genes in human colon cancer and metabolomics analyses were used to identify pathways regulated by LEF1 in MYC expressing cells.

resultsMYC regulates the levels of numerous WNT-related genes, including the β-catenin co-transcription factor LEF1. MYC activates the transcription of LEF1 and is required for LEF1 expression in colon cancer cells and in primary colonic cells transformed by APC loss of function, a common mutation in colon cancer patients. LEF1 caused the retention of β-catenin in the nucleus, leading to the activation of the WNT pathway in MYC-expressing cells. Consequently, MYC-expressing cells were sensitive to LEF1 inhibition. Moreover, we describe two examples of genes induced in MYC-expressing cells that require LEF1 activity: the peroxisome proliferator activated receptor delta (PPARδ) and the Acyl CoA dehydrogenase 9 (ACAD9).

conclusionsWe demonstrated that MYC is a transcriptional regulator of LEF1 in colonic cells. Our work proposes a novel pathway by which MYC regulates proliferation through activating LEF1 expression which in turn activates the WNT pathway.

Indexed as

Transcriptional ActivationWnt Signaling PathwayAcyl-CoA Dehydrogenasesbeta CateninCell LineCell ProliferationColonic NeoplasmsGene Knockdown TechniquesHumansLymphoid Enhancer-Binding Factor 1PPAR deltaProto-Oncogene MasProto-Oncogene Proteins c-mycACAD9 protein, humanAcyl-CoA Dehydrogenasesbeta CateninLEF1 protein, humanLymphoid Enhancer-Binding Factor 1MAS1 protein, humanMYC protein, humanPPAR deltaProto-Oncogene MasProto-Oncogene Proteins c-mycACAD9Colon cancerLEF1MetabolismMYCPPARδProliferationTumorigenesisWNT/β-catenin pathway

Identifiers

PMID31623618
PMCPMC6798382
OpenAlexW2980616295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.